Reaction mass of disodium 2-[[2-hydroxy-3-[[methyl-(2-oxido-2-oxoethyl)amino]methyl]-5-nonylphenyl]methyl-methylamino and sodium 2-[(2-hydroxy-5-nonylphenyl)methyl-methylamino]acetate

Endpoint summary

Description of key information

The acute oral toxicity of the substance, the Reaction mass of disodium N,N’-[(2-hydroxy-5-nonylphen-1,3-ylene)bis(methylene)]bis[N-methylaminoacetate] and sodium N-[(2-hydroxy-5-nonylphenyl)methyl]-N-methylaminoacetate the has been investigated in female Wistar rats a fixed dose procedure acute oral toxicity study conducted according to OECD TG 420. The acute oral LD50 of the substance was determined to be > 2000 mg/kg bw. No acute toxicity studies have been carried out via the inhalation or dermal routes. A waiver is proposed for acute inhalation toxicity based on the physiochemical properties of the substance. Additionally, a waiver is proposed for acute dermal toxicity based on the low acute oral toxicity of the substance.

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

Experimental Start: 23 October 2018 Experimental Completion: 13 November 2018

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Justification for type of information:

Annex VIII Data Requirement

Qualifier:

according to guideline

Guideline:

OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)

Version / remarks:

2001

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Test type:

fixed dose procedure

Limit test:

yes

Species:

rat

Strain:

Wistar

Sex:

female

Details on test animals or test system and environmental conditions:

Female Wistar (RccHan™:WIST) strain rats were supplied by Envigo RMS (UK) Limited, Oxon, UK. The females were nulliparous and non-pregnant. After an acclimatization period of at least 5 days the animals were selected at random and given a number unique within the study by indelible ink-marking on the tail and a number written on a cage card. At the start of the study the animals were 8 to 12 weeks of age. The body weight variation did not exceed ±20% of the mean body weight at the start of treatment.

The animals were housed in groups of up to four in suspended solid-floor polypropylene cages furnished with woodflakes. With the exception of an overnight fast immediately before dosing and for approximately 3 to 4 hours after dosing, free access to mains drinking water and food (2014C Teklad Global Rodent diet supplied by Envigo RMS (UK) Limited, Oxon, UK) was allowed throughout the study. The diet, drinking water and bedding were routinely analyzed and were considered not to contain any contaminants that would reasonably be expected to affect the purpose or integrity of the study.

The temperature and relative humidity were set to achieve limits of 19 to 25 °C and 30 to 70% respectively. The rate of air exchange was at least fifteen changes per hour and the lighting was controlled by a time switch to give 12 hours continuous light and 12 hours darkness.

Route of administration:

oral: gavage

Vehicle:

arachis oil

Details on oral exposure:

All animals were dosed once only by gavage, using a metal cannula attached to a graduated syringe. The volume administered to each animal was calculated according to the fasted body weight at the time of dosing. Treatment of animals was sequential. Sufficient time was allowed between each dose group to confirm the survival of the previously dosed animals. The dose volume was 10 mL/kg.

Doses:

300 mg/kg - 1 female
2000 mg/kg - 1 female
2000 mg/kg - 4 females

No. of animals per sex per dose:

300 mg/kg - 1 female
2000 mg/kg - 5 females

Control animals:

no

Details on study design:

All animals were dosed once only by gavage, using a metal cannula attached to a graduated syringe. The volume administered to each animal was calculated according to the fasted body weight at the time of dosing. Treatment of animals was sequential. Sufficient time was allowed between each dose group to confirm the survival of the previously dosed animals.

Clinical observations were made 30 minutes, 1, 2, and 4 hours after dosing and then daily for up to 14 days. Morbidity and mortality checks were made twice daily, early and late during normal working days, and once daily at weekends and public holidays.

Individual body weights were recorded on Day 0 (the day of dosing) and on Days 7 and 14.

At the end of the observation period the animals were killed by cervical dislocation. All animals were subjected to gross necropsy. This consisted of an external examination and opening of the abdominal and thoracic cavities. The appearance of any macroscopic abnormalities was recorded. No tissues were retained.

Statistics:

None

Key result

Sex:

female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Mortality:

None

Clinical signs:

other: Hunched posture was noted in all animals during the day of dosing and persisted in one animal one day after dosing. Noisy respiration was also noted in one animal during the day of dosing.

Gross pathology:

NAD

Other findings:

None

Interpretation of results:

GHS criteria not met

Conclusions:

The acute oral median lethal dose (LD50) of the test item in the female Wistar strain rat was estimated to be greater than 2000 mg/kg body weight (Globally Harmonized Classification System − Unclassified).

Executive summary:

Introduction

 

The study was performed to assess the acute oral toxicity of the test item in the Wistar strain rat.

 

Methods

 

Following sighting tests at dose levels of 300 mg/kg and 2000 mg/kg, an additional four fasted female animals were given a single oral dose of test item, as a suspension in arachis oil BP, at a dose level of 2000 mg/kg body weight. Clinical signs and body weight development were monitored during the study. All animals were subjected to gross necropsy.

 

Results

 

Mortality:There were no deaths.

 

Clinical Observations:Hunched posture with or without noisy respiration was noted in all animals treated at a dose level of 2000 mg/kg. No signs of systemic toxicity were noted in the animal treated at a dose level of 300 mg/kg.

 

Body Weight:Animals showed expected gains in body weight over the observation period except for one animal which showed a body weight loss (approximately 3.4%) over the second week.

 

Necropsy:No abnormalities were noted at necropsy.

 

Conclusion

 

The acute oral median lethal dose (LD50) of the test item in the female Wistar strain rat was estimated to be greater than 2000 mg/kg body weight (Globally Harmonized Classification System − Unclassified).

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

LD50

Value:

2 000 mg/kg bw

Quality of whole database:

Study is GLP compliant and reliable without restrictions.

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no study available

Acute toxicity: via dermal route

Endpoint conclusion

Endpoint conclusion:

no study available

Additional information

Acute Oral Toxicity

The acute oral toxicity of the substance, the Reaction mass of disodium 2,2'-[(2-hydroxy-5-nonyl-1,3-phenylene)bis[methylene(methylimino)] diacetate and sodium [(2-hydroxy-5-nonylbenzyl)(methyl)amino]acetate, has been investigated in female Wistar rats in an acute oral toxicity study conducted according to OECD TG 420 using the fixed dose procedure. Sighting tests were initially carried out in which two fasted rats where respectively administered the test substance, as a suspension in arachis oil BP, via oral gavage at dose levels of 300 mg/kg and 2000 mg/kg. An additional four fasted female animals were subsequently given a single oral dose of test item, at a dose level of 2000 mg/kg body weight.

No mortalities were reported in the study. Clinical observations of hunched posture with or without noisy respiration were noted in all animals treated at a dose level of 2000 mg/kg. No signs of systemic toxicity were noted in the animal treated at a dose level of 300 mg/kg. Animals showed expected gains in body weight over the observation period except for one animal which showed a body weight loss (approximately 3.4%) over the second week. No abnormalities were noted at necropsy.

The acute oral median lethal dose (LD50) of the substance was determined to be > 2000 mg/kg bw in female Wistar rats. Based on the findings of the study, the substance does not meet the criteria for classification for acute oral toxicity according to Regulation (EC) 1272/2008.

Acute Inhalation Toxicity

No data are available and no studies are required. A waiver is proposed: based on the physicochemical properties of the substance, significant exposures via the inhalation route are unlikely. Furthermore, the substance has low acute toxicity via the oral route and is unlikely to pose as an acute hazard via the inhalation or the dermal routes.  

Acute Dermal Toxicity

No data are available and no studies are required. A waiver is proposed based on the low acute oral toxicity of the substance. Substances with low acute oral toxicity are unlikely to present an acute toxicity hazard via the dermal route and testing in this regard is therefore unjustified.

Justification for classification or non-classification

The acute oral median lethal dose (LD50) of the substance was determined to be > 2000 mg/kg bw in female Wistar rats in an acute toxicity study conducted according to OECD TG using the fixed dose procedure. Based on the findings of the study, the substance does not meet the criteria for classification for acute oral toxicity according to Regulation (EC) 1272/2008.